According to Santos et al.’s study on xenograft models of lung cancer, administering a new anti-FAP monoclonal antibody, FAP5-DM1, can either obstruct tumor growth for an extended time period or completely inhibit the tumor, causing tumor regression. Here, FAP is linked to neoplasm.